FDA clears Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
Genzyme's venglustat tablets are approved for adults and children from 15 kg, with psychiatric risks flagged in the safety information. Much of the detail that matters to teams is not yet public.
What happened
On 18 November 2026 the US Food and Drug Administration approved Infilbray (venglustat) tablets, from Genzyme, a Sanofi unit. The agency describes it as the first treatment for the neurological symptoms of Type 3 Gaucher disease. The approval covers adults and children weighing at least 15 kg.
The FDA's announcement also highlights psychiatric risks in the product's safety information. The records available to us do not say how those risks are presented in the label, what monitoring is required, or whether any risk-management programme applies. We therefore do not characterise them beyond what the FDA has said.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease FDA · Wed 18 Nov 2026
- EEA Joint Committee extends three EU feed additive rules to Iceland and Norway EUR-Lex · Thu 19 Nov 2026
- Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs Health Canada · Wed 18 Nov 2026
- INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown INFARMED · Wed 18 Nov 2026
- Commission publishes minutes of SCHEER working group meeting on brain stimulators European Commission (DG SANTE) · Wed 18 Nov 2026
- AIFA reminds sponsors how to pay Annual Safety Report evaluation fee AIFA · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.